Karyopharm Therapeutics (NASDAQ:KPTI) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a buy rating in a research report released on Thursday.

Other equities research analysts have also recently issued reports about the stock. Royal Bank of Canada restated an outperform rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday. Robert W. Baird reduced their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an outperform rating for the company in a report on Wednesday. Finally, HC Wainwright reiterated a buy rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $4.80.

Karyopharm Therapeutics Price Performance

Shares of KPTI traded down $0.03 during trading hours on Thursday, hitting $0.81. 329,705 shares of the stock were exchanged, compared to its average volume of 1,487,917. The firm has a market capitalization of $100.94 million, a P/E ratio of -0.64 and a beta of 0.21. The business has a 50-day moving average of $0.93 and a 200-day moving average of $1.12. Karyopharm Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $33.13 million during the quarter, compared to analyst estimates of $35.02 million. As a group, analysts forecast that Karyopharm Therapeutics will post -1.16 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Deepika Pakianathan sold 360,744 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $1.00, for a total transaction of $360,744.00. Following the transaction, the director now directly owns 11,209 shares of the company’s stock, valued at $11,209. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 1,279,081 shares of company stock worth $1,237,898 over the last three months. 4.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in shares of Karyopharm Therapeutics during the second quarter valued at about $167,000. Ikarian Capital LLC lifted its position in shares of Karyopharm Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after purchasing an additional 9,355 shares in the last quarter. Simplicity Wealth LLC bought a new stake in Karyopharm Therapeutics in the first quarter worth about $66,000. Monashee Investment Management LLC bought a new stake in Karyopharm Therapeutics in the fourth quarter worth about $115,000. Finally, Panagora Asset Management Inc. bought a new stake in Karyopharm Therapeutics in the fourth quarter worth about $197,000. 66.44% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).